在患有骨髓瘤的儿科患者中减肥和对化疗的反应
Yair Peled1, Dror Levin2, Michal Manisterski2
1Department of Pediatric Hemato-Oncology, Dana Children's Hospital, Tel Aviv Medical Center, Tel Aviv, Israel, affiliated to the Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. yairpeled7@gmail.com.
European journal of clinical nutrition
|January 18, 2024
概括
在化疗期间体重减轻的小儿骨质肉瘤患者对治疗反应更好. 这种体重减轻可能表明有益的热量限制效应,需要进一步研究.
科学领域:
- 儿科瘤学 儿科瘤学
- 癌症研究 癌症研究
- 营养科学 营养科学
背景情况:
- 儿童癌症患者经常出现体重减轻和营养不良.
- 在儿科瘤学中减肥的预后影响受到争议.
- 这项研究调查了减肥与骨髓瘤中新辅助化疗反应的相关性.
研究的目的:
- 为了确定体重减轻和儿科骨髓瘤化疗反应之间的关系.
- 为了探索减肥是否影响治疗疗效.
主要方法:
- 从单个儿科血液瘤中心 (2011-2022) 的医疗档案的回顾性审查.
- 包括63名儿科骨髓瘤患者.
- 提取从化疗开始到瘤切除的体重变化.
主要成果:
- 发现体重减轻 (≥3%) 和化学疗法的积极反应之间存在显著的直接相关性.
- 通过超过90%的化学疗法后瘤缩表明了良好的反应.
- 体重减轻似乎是化疗反应的积极预后指标.
结论:
- 化疗期间低热量摄入可能会模仿有益的热量限制饮食.
- 需要进行进一步的前性研究,以建立最佳热量摄入指南.
- 这一发现表明,潜在的营养干预措施可以改善骨髓瘤治疗结果.
更多相关视频
02:35Author Spotlight: Replicating Human Osteosarcoma Progression in Immunodeficient Mice for Cancer Study
Published on: March 22, 2024
826
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.5K
相关概念视频
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Bone Disorders
3.5K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
3.5K
Cancer Survival Analysis
353
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
353
